JAMP DARIFENACIN 7.5 MG
DARIFENACIN (DARIFENACIN HYDROBROMIDE) : 7.5 MG · DIN 02491869 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP DARIFENACIN?
JAMP DARIFENACIN 7.5 MG contains DARIFENACIN (DARIFENACIN HYDROBROMIDE) : 7.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02491869, held by JAMP PHARMA CORPORATION, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Dec-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02491869 |
|---|---|
| Brand name | JAMP DARIFENACIN |
| Generic / active ingredient | DARIFENACIN (DARIFENACIN HYDROBROMIDE) : 7.5 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 7.5 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD10 DARIFENACIN |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Dec-2021 |
What can be used instead?
Other Canadian products sharing ATC code G04BD10 DARIFENACIN. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DARIFENACIN | 15 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452529 |
| APO-DARIFENACIN | 7.5 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452510 |
| ENABLEX | 15 MG | TABLET (EXTENDED-RELEASE) | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02273225 |
| ENABLEX | 7.5 MG | TABLET (EXTENDED-RELEASE) | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02273217 |
| JAMP DARIFENACIN | 15 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02491877 |
Who else supplies DARIFENACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DARIFENACIN appears in 22 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.